CRESCITA THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.435 CAD | 0.00% |
|
+3.57% | -11.22% |
| Mar. 13 | Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share | MT |
| Mar. 13 | Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023. | CI |
| Sales 2022 | 23.52M 17.1M | Sales 2023 | 17.52M 12.74M | Capitalization | 9.79M 7.12M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 | Net income 2023 | -1M -727K | EV / Sales 2022 | 0.29 x |
| Net cash position 2022 | 6.7M 4.87M | Net cash position 2023 | 8.13M 5.91M | EV / Sales 2023 | 0.09 x |
| P/E ratio 2022 |
16.5
x | P/E ratio 2023 |
-4.9
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.65% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +3.57% | ||
| 1 week | +3.57% | ||
| Current month | -3.33% | ||
| 1 month | +8.75% | ||
| 3 months | -19.44% | ||
| 6 months | -25.00% | ||
| Current year | -11.22% |
1 week
0.42
0.44
1 month
0.380.49
Current year
0.360.57
1 year
0.360.73
3 years
0.360.91
5 years
0.361.23
10 years
0.351.99
| Managers | Title | Age | Since |
|---|---|---|---|
Serge Verreault
CEO | Chief Executive Officer | - | - |
Jose DaRocha
DFI | Director of Finance/CFO | - | 17-08-31 |
Daniel Chicoine
CHM | Chairman | 70 | 16-02-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 16-02-29 | |
Daniel Chicoine
CHM | Chairman | 70 | 16-02-29 |
John London
BRD | Director/Board Member | - | 16-02-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.435 | 0.00% | 3 761 |
| 24-04-18 | 0.435 | +3.57% | 3,000 |
| 24-04-17 | 0.42 | 0.00% | 1,173 |
| 24-04-11 | 0.42 | 0.00% | 23,000 |
| 24-04-10 | 0.42 | -4.55% | 12,500 |
Delayed Quote Toronto S.E., April 18, 2024 at 03:14 pm EDT
More quotes
Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. It also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER and Obagi Medical in Canada. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Companyâs contract development and manufacturing organization infrastructure, and sales of product development services.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -11.22% | 6.2M | |
| +27.97% | 672B | |
| +23.45% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.47% | 211B | |
| -0.38% | 203B | |
| -9.94% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- CTX Stock
